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Background: Breast cancer is a complex heterogeneous disease and is one of the leading causes of death among
women. In addressing the need for treatments of this life-threatening illness, we studied 3,4-dihydropyrimidin-2
(1H)-one (or thione) derivatives (DHPMs), a class of inhibitor molecules of the Eg5 motor spindle protein that shows
pronounced antitumor activity against several cancer cell lines.
Methods: An in vitro screening was performed for identification of DHPMs with potent antitumor effects on MCF-7
and MDA-MB-231 cells and the selected DHPMs were evaluated for their inhibitory activity on Eg5 both in silico,
using Molecular dynamics, and in vitro Eg5 inhibition assays. Analysis of cell death induction, proliferation, cell cycle
and cancer stem cells (CSC) profile were performed by flow cytometry to assess the influence of the selected DPHMs on
these important tumor features. Finally, the effects of DHPM treatment on tube formation were evaluated in vitro using
HUVEC cells, and in vivo using a model on chorioallantoic membrane (CAM) of fertilized eggs.
Results: We identified five DHPMs with pronounced inhibitory activity on Eg5 motor protein interfering with the proper
mitotic spindle assembly during cell division. These compounds impair the correct conclusion of cell cycle of the breast
cancer cells and showed to be selective for tumor cells. Moreover, DHPMs modulate the CD44+/CD24− phenotype
leading to a decrease in the CSC population in MDA-MB-231 cells, an important effect since CSC are resistant to many
conventional cancer therapies and play a pivotal role in tumor initiation and maintenance. This observation was
confirmed by the results which demonstrated that DHPM treated cells had impaired proliferation and were unable to
sustain angiogenesis events. Finally, the DHMP treated cells were induced to apoptosis, which is one of the most pursued
goals in drug development.
Conclusions: The results of our study strongly suggest that DHPMs inhibit important tumorigenic features of breast
cancer cells leading them to death by apoptosis. These findings firmly point to DHPM molecular architecture as a
promising alternative against breast cancer.
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Breast cancer remains the most common malignancy
among women and the leading cause of death, accounting
for 14% of the total estimated deaths attributed to cancer in
women [1,2]. In order to face this life-threatening illness, the
search for new molecules capable of targeting mitosis with-
out disrupting microtubule dynamics has significantly in-
creased to be applied in new antineoplastic therapies [3-5].
A promising alternative to eliminate cancer cell mitotic
progression relies on interference in the function of some
essential mitosis molecules such as microtubule-associated
proteins, particularly spindle motor proteins [6,7].
Kinesin Eg5 is one fundamental spindle motor protein
and its specific role during mitosis in the assembly and
maintenance of the bipolar spindle has rendered it an at-
tractive therapeutic target that could prevent cell cycle
progression through mitosis and promote tumor growth
regression [8-10]. Inhibition of Kinesin Eg5 stops cen-
trosome migration to the polar region resulting in a
monoastral spindle formation [11,12], and this abnormal
phenotype plays a critical role in activation of the mitotic
spindle assembly checkpoint (SAC). The SAC promotes
mitotic arrest at metaphase/anaphase transition through
the maintenance of cdc2/cyclin B activity [8,11,13].
In addition to proliferative events that maintain tumor
development, some cancer cells also have the ability to
invade and colonize restricted areas belonging to other
tissue types essentially through a process observed in
malignant tumors named metastasis [14]. Invasion and
metastasis are landmark angiogenesis-dependent events
that transform a locally growing tumor into a systemic,
metastatic and severe life-threatening disease [15,16].
Cancer Stem Cells (CSC), also known as initiating can-
cer cells, play a key role in the emergence of typical neo-
plastic hallmarks. These cells are able to dictate invasion,
metastasis, heterogeneity, and therapeutic resistance in
tumors [17,18]. Furthermore, CSC are capable of self-
renewal and differentiation, and as such play a pivotal role
in tumor initiation and maintenance together with spread-
ing cancer cells to regional lymph nodes and later to other
tissues and organs [19].
Resistance of putative CSC against many conventional
cancer therapies is associated with two main characteris-
tics: 1) a slow cell division rate; and 2) the ability to ef-
flux antitumor drugs [20]. Furthermore, CSC undertake
an important role in the relapse of patients post-treatment
and could therefore be responsible for the incurable na-
ture of many advanced solid tumors including metastatic
breast cancer [21]. The aforementioned CSC features
make these cells potential targets for cancer treatment by
specific compounds that act by modulating mesenchymal-
epithelial transition.
In recent years, compounds that specifically in-
hibit Eg5 function have been identified, such as 3,4-dihydropyrimidin-2(1H)-one (or thione) (DHPMs) [22-24].
These molecules comprise a class of heterocyclic com-
pounds obtained through Biginelli reaction that has monas-
trol as their prototype [25]. The Eg5 inhibition by DHPMs
is considered an attractive approach to cancer treatment
since mitotic kinesins are exclusively involved in the forma-
tion and function of the mitotic spindle, and some of them
are only expressed in proliferating cells [26]. The Eg5 in-
hibitors therefore not interfere with other microtubule-
dependent processes [27,28], which are the main reason
for the neurotoxicity of anti-microtubule agents [29]. It
was shown that monastrol has antitumor activity against
diverse cancer cell types such as renal, breast and glioma
cell lines [24,30].
Here, we provide the results of a study based on the
activity of thirty-seven DHPM derivatives, recently de-
scribed [31] by our group, on breast cancer cells. In
addition, we identified and functionally characterized
the compounds that provide potent DHPM-dependent
Kinesin Eg5 inhibition, and were capable of impairing
metaphase/anaphase transition together with cell pro-
liferation. Moreover, the DHPMs induce CSC differen-
tiation into epithelial phenotype, which can controls
essential properties to establishment, progression and
recrudescence of tumors. Finally, the DHPM derivatives




A detailed description is available in Additional file 1.
Cells and cell culture
MCF-7 and MDA-MB-231 cell lines were used as
model of breast cancer cells in this work. Our choice
was based mainly on the fact that breast cancer is the
most prevalent type of cancer in women worldwide
and also because of the differences on metastasis cap-
ability and cancer stem cells population in these cell
lines. These features affect the cell cycle and mitosis
rate, which are directed linked with the predicted
DHPMs effect.
MCF-7 cell line and primary culture of connective tis-
sue cells were provided by the Laboratory of Morph-
ology, University of Brasília (Brasília, BR). MDA-MB-231
cells were purchased from Rio de Janeiro Cell Bank
(RJCB - Rio de Janeiro, BR). Cell line characterization
and authentication was conducted by RJCB using short
tandem repeat profiling. Primary culture cells were taken
from healthy human dental pulp predominantly consist-
ing of fibroblasts and were used as normal control cells.
MCF-7 cells and fibroblasts were grown in complete
DMEM and maintained at 37°C with 5% CO2. MDA-
MB-231 cells were grown in Leibovitz L15 medium at
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with 10% fetal bovine serum and 25 μg/mL of gentamicin.
Catalytic synthesis of the 3,4-dihydropyrimidin-2(1H)-one
(or thione) derivatives (DHPMs)
The thirty-seven compounds tested in this work (Table 1)
were provided by the Laboratory of Medicinal and
Technological Chemistry, University of Brasília, and syn-
thesized by the catalytic Biginelli reaction as previously
described [31].
Cell viability assays
Fibroblasts, MCF-7 (both 3 × 103/well) and MDA-MB-
231 (5 × 103/well) cells were plated in 96-well plates and
treated with DHPMs for 24, 48 and 72 h. Cytotoxicity
was determined using 3-(4,5-dimethylthiazol-2-yl)-2,5-
diphenylterazolium bromide (MTT) according to the
manufacturer’s instructions. Absorbance readings were
measured by a spectrophotometer. Cell viability was nor-
malized to control (vehicle only).
Molecular dynamics
Molecular dynamics simulations (MD) of the Eg5 pro-
tein and Eg5 protein complexes with each of the five
tested compounds were conducted in an aqueous envir-
onment, using the Single Point Charge – SPC – water
model [32]. Analyses were performed using the GRO-
MACS 4 computer package [33]. The dynamics utilized
the 3-D protein model, collected from PDB (PDB-ID
1X88), as the initial structure. The ensembles were
immersed in approximately 65,600 water molecules in
dodecahedral boxes with a minimum distance of 0.7 nm
between complex-box frontiers. Sodium ions were also
inserted in the ensembles in order to neutralize system
charges. (See details in the Additional file 1).
Kinesin inhibition assay
Kinesin inhibition assays were performed using Kinesin
ELIPA (Enzyme Linked Inorganic Phosphate Assay). Re-
actions were conducted in 96-well plates according to
the manufacturer’s recommendations (Kinesin ELIPA
Biochem Kit – BK060). The half maximal inhibitory con-
centration of each compound was added to the reactions
(4 m - 197.3 μM; 4bt (known as dimethylenastron) -
126.9 μM; 4p - 87.54 μM; 4bc - 234.9 μM; 4x - 276.5 μM
and monastrol – 110.4 μM) with readings taken at 30-
second intervals for 30 minutes at room temperature
using a spectrophotometer at 360 nm.
α-tubulin immunostaining
Aliquots of 7 × 104 MCF-7 cells were seeded onto
12 mm round glass coverslips placed in the base of each
well of a 24-well plate. After adhesion, cells were treated
for 24 and 48 h with the pre-selected compounds attheir maximum non-cytotoxic concentrations to normal
cells or incubated with culture medium only for the
same duration (negative control). Cells were washed
with PBS, fixed with 3.7% formaldehyde, permeabilized
with 0.1% Triton X-100 and blocked in PBS supple-
mented with 1% skimmed milk, 2.5% bovine serum albu-
min (BSA) and 8% fetal bovine serum (FBS) at room
temperature. Cells were incubated overnight with mouse
anti-α-tubulin antibody (1:500) at 4°C, followed by incu-
bation with a secondary antibody: Alexa Fluor 488 rabbit
anti-mouse IgG (1:400), for 1 hour at 37°C. Nuclei were
stained with 300 nM DAPI. The coverslips were mounted
with ProLong Gold Antifade and specimens observed under
a laser scanning confocal microscope.
Transmission electron microscopy analysis
Aliquots of 8 × 105 MCF-7 cells were seeded in 12-well
plates and ultra-structural analysis performed on con-
trols or after 48 h of treatment with 4p (0.4 mM). Cells
were washed twice with PBS and fixed overnight with
glutaraldehyde (2.5%) at 4°C. Cells were subsequently
washed with 0.1 M sodium cacodylate buffer (pH 7.2)
and post-fixed in 1% osmium tetroxide and 0.8% potas-
sium ferricyanide (10 mM CaCl2 in 0.2 M sodium caco-
dylate buffer). Samples were washed twice with 0.1 M
sodium cacodylate buffer (pH 7.2) and in-block staining
was performed for 16 h with 0.5% uranyl acetate at 4°C.
Cells were dehydrated in a graded acetone series (50-
100%) and embedded in Spurr resin. Ultrathin sections
were observed in a Jeol® 1011 transmission electron
microscope (TEM) at 80 kV.
Flow cytometry analysis
MCF-7 and MDA-MB-231 cells were seeded (1 × 105) in
12-well plates and treated with the five pre-selected
DHPMs for the determined time for each experiment.
Treatment for apoptosis assay, cancer stem cell, and cell
cycle analysis was conducted using 4 m (1 mM), 4bt
(dimethylenastron, 0.8 mM), 4p (0.4 mM), 4bc (1.0 mM),
4x (0.8 mM) and monastrol (positive control, 1.0 mM).
For proliferation assays, cells were treated with IC50 con-
centrations of each compound. Adherent and floating cells
were harvested at the same tube and pelleted by centrifu-
gation at 300 g for 5 minutes and stained. Data acquisition
of these two fractions put together was performed on a
FACSCalibur flow cytometer using CellQuest software
and analysed using the FloJo Software.
Apoptosis and necrosis assay
Untreated control cells and DHPMs-treated for 72 h cell
samples were stained with Annexin-V-FITC or Annexin-V-
Alexa Fluor® 680 and propidium iodide according to the
manufacturer’s instructions.
Table 1 Synthesized DHPM derivatives
Ent Reagent Prod. Yield (%)
R1 R2 R3 X
1 Ph Me Me O 4c 99
2 Ph OCH2CH3 Me S 4d 93
3 Ph Me Me S 4e 83
4 4-Cl-Ph OCH2CH3 Me O 4f 87
5 4-Cl-Ph OCH2CH3 Me S 4h 80
6 4-Cl-Ph Me Me S 4i 77
7 3-OH-Ph OCH2CH3 Me O 4j 98
8 3-OH-Ph Me Me O 4k 80
9a 3-OH-Ph OCH2CH3 Me S Mon 93
10 3-OH-Ph Me Me S 4m 88
11 2-OH-Ph OCH2CH3 Me O 4n 84
12 2-OH-Ph Me Me O 4o 80
13 2-OH-Ph OCH2CH3 Me S 4p 84
14 2-OH-Ph Me Me S 4q 90
15 3-NO2-Ph OCH2CH3 Me O 4r 96
16 3-NO2-Ph OCH2CH3 Me S 4t 86
17 3-NO2-Ph Me Me S 4u 86
18 2-NO2-Ph OCH2CH3 Me O 4v 70
19 2-NO2-Ph Me Me O 4x 60
20 2-NO2-Ph Me Me S 4z 60
e
21 4-OH-3-MeO-Ph OCH2CH3 Me O 4ba 98
22 4-OH-3-MeO-Ph OCH2CH3 Me S 4bc 85
23 4-OH-3-MeO-Ph Me Me S 4bd 85
24 H OCH2CH3 Me O 4be 96
25 Me Me Me O 4bj 66
26 Me OCH2CH3 Me S 4bk 70
27 OCH2CH3 Me O 4bm 87
28 Me Me O 4bn 79
29b OCH2CH3 Me S 4bo 70
30 Me Me S 4bp 71
31 3-OH-Ph O 4bq 60
32c 3-OH-Ph S 4br 72
33 3-OH-Ph O 4bs 70
Table 1 Synthesized DHPM derivatives (Continued)
34d 3-OH-Ph S 4bt 70
35 OCH2CH3 Me O 4bu 66
f
36 Me Me S 4bv 50f
37 OCH2CH3 Me S 4bx 42
f
38 Me Me O 4by 83
aMonastrol. bPiperastrol. cEnastron. dDimethylenastron. e12 h of reaction.
fProduct formation was above 90%, but there was considerable loss during
purification column chromatography.
37 DHPM derivatives and monastrol were studied in this work.
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Expression level of CD44 and CD24 in treated and con-
trol MCF-7 or MDA-MB-231 cells was measured after
24 h of treatment. Cells were washed in PBS with 1%
BSA. Antibodies against CD44-FITC and CD24-PE were
added at the dilution suggested by the manufacturer in
PBS/1% BSA and incubated on ice for 30 minutes.
Proliferation assay
MCF-7 and MDA-MB-231 cells were labeled with 5-
(and 6-)-carboxyfluorescein diacetate succinimidyl ester
(CFSE) prior to culture. After adhesion, cells were
treated with DHPMs or maintained in culture medium
only (control) for 72 h. The percentage of proliferative
cells was calculated based on the CFSE fluorescence pro-
file analysis of the tested samples compared to that of
the fixed undivided control cells (treated with 10 μM of
colchicine) using the FlowJo software.
Cell cycle analysis
Control and DHPM-treated cells were harvested at 24,
48 and 72 h, resuspended in ice-cold PBS and fixed with
70% ethanol on ice. Cells were then washed with PBS,
harvested and incubated with propidium iodide solution
(0.1% Triton X-100, 10 μg/mL propidium iodide,
100 μg/mL DNase free RNase) for 10 min at 37°C. For
analysis of cell populations in each cell cycle phase, the
sub-G1 picks were excluded and the plots were gener-
ated by cell cycle platform data analysis by the FlowJo
Software.
HUVEC tube formation assay
The anti-angiogenic potential of DHPMs was tested using
an in vitro Angiogenesis Assay Kit according to the manu-
facturer’s instructions. Aliquots of 8 × 103 HUVEC cells
were resuspended in medium supplemented with endo-
thelial cell growth supplement (1 DMEM:1 RPMI, 2%
SFB, 25 μg/ml gentamicin, 15 μg/ml ECGS) with or with-
out 30 μM, IC50 or 300 μM of DHPM treatment and were
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96-well plates. These plates were incubated for 11 hours at
37°C, in 5% CO2. Wells were subsequently photographed
using an inverted light microscope at 20x magnification
and tube formation analyzed. Seven fields per group of 3 in-
dependent experiments were quantified by pattern recogni-
tion according to manufacturer’s instructions.
Chorioallantoic membrane (CAM) assay
DHPM anti-angiogenic potential was also tested in vivo
using a CAM assay performed according to Ribatti, [34]
with some experimental time adaptations according to Sun
et al. [35]. A minimum of 3 fertilized eggs was used per
group. On the 10th day, 1 × 105 MCF-7 or MDA-MB-231
cells resuspended in supplemented culture medium (experi-
mental control) or in medium supplemented with 500 ng
of compounds 4 m, 4bt (dimethylenastron), 4p, 4bc, 4x,
monastrol and genistein (as the anti-angiogenic control)
were implanted into a chorioallantoic membrane (CAM) in
a 2 mm2 hydrolysate collagen hemostatic sponge. Blood
vessels were quantified on the 17th day by Wimasis Image
Analysis. All blood vessels emerging from the grafts were
included in the quantification.
Statistical analysis
The quantitative results are presented as the mean ±
SEM for at least three repeated individual experiments
for each group. Statistical analyses were performed using
GraphPad Prism 5 Software. Statistical significance of
differences was determined by ANOVA with post-hoc
comparison by the Bonferroni test. A P value of <0.05 was
considered statistically significant.
Results
DHPM derivatives produce a dose and time dependent
cytotoxicity and are selective for tumor cells
Monastrol (a DHPM derivative) was the first known
small cell-permeable molecule with potential inhibitory
properties against the mitotic machinery [11]. Our work
is based on compounds with the same monastrol scaf-
fold, that are, 37 newly synthesized 3, 4-dihydropyrimi-
din-2(1H)-one (or thione) derivatives (see structures in
Table 1). Preview screen tests were conducted in order
to identify high antitumor activity against human breast
tumor cells together with fewer side effects on normal
cells. After 72 h of treatment, 10 of 37 compounds
induced ≥ 60% of MCF-7 cells to death and 30 de-
monstrated the same activity on MDA-MB-231 cells
(Additional file 2: Figure S1). Five of the DHPMs: 4 m,
4bt (dimethylenastron), 4p, 4bc and 4x showed the high-
est activities leading to a significant decrease in cell
viability in both cell lines at all concentrations tested
(100 μM – 1.00 mM) (Figure 1A).To establish the optimal treatment concentration for
each one of these five compounds, a cell viability assay
with human fibroblasts (normal cells) was conducted
using concentrations that induce at least 70% of death
in breast tumor cells in both cell lines at 72 h of treat-
ment. The highest concentration of each derivative
that did not show any significant cytotoxic effects on
normal cells (maximum non-cytotoxic concentration
to normal cells) was selected to conduct further experi-
ments (Figure 1B and Table 2). This experiment shows
that with exception of the 4p, compounds have selectivity
for tumor cells as they are in general, dose-dependent for
tumor cells, but not for normal cells.
The half maximal inhibitory concentration (IC50) was
calculated based on the treatment of tumor cells for
72 h (Table 2). The IC50 values obtained from MDA-MB-
231 cells treated with 4 m, 4bt (dimethylenastron) and 4p
derivatives were smaller than those achieved from monas-
trol. Although 4bc and 4x show higher concentrations
associated to IC50, their activities are not dose dependent
for normal cells as they were for tumor cells (Figure 1B).
Finally, the observed activity of these five selected mole-
cules shows time-dependent effects with the best time for
treatment defined as 72 h (Figure 1C).
DHPMs induce severe morphological alterations in breast
tumor cells
The five selected derivatives produced significant mor-
phological alterations to MDA-MB-231 cells after 72 h of
treatment (Figure 2). Only the 4bt (dimethylenastron), 4p
and 4bc derivatives produced the same results with MCF-7
cells under the same treatment conditions (Figure 2).
These changes were characterized by a reduction in cell
size, absence of focal adhesion points, rounded morph-
ology and minor cell detachment from the surface where
they had been seeded. A significant reduction of cell num-
ber on the cover slips from treated groups in comparison
to the control group was also observed. This feature sug-
gests that many cells died as a result of the actions of the
derivatives used (Figure 2). The 4 m and 4x derivatives
caused no significant alterations to MCF-7 cells, similar to
the observed with untreated control samples (Figure 2).
DHPMs influence kinesin Eg5 movements in different ways
Molecular dynamics assays were performed in order to
verify the binding pattern and influence of the five
DHPMs on Eg5 behavior. It is believed that the protein’s
movements exert important influence over its activity
[36]. Thus, the in silico study of induced protein stiffening,
together with the in vitro data, may provide an interesting
overview of the link between derivative impact on protein
movements and its inhibitory activity.
The different binding patterns observed for the DHPM
derivatives tested (Figure 3) show that the interaction
Figure 1 DHPM derivatives produce a dose and time dependent cytotoxicity and are selective for tumor cells. A, MCF-7 and MDA-MB-231 cells were
treated for 72 h with 4 m, 4bt (dimethylenastron), 4p, 4bc and 4x (100 μM – 1 mM) and cell viability evaluated by the MTT assay. Columns, mean of
viable cells; bars, SEM; ***(P < 0.001). B, Fibroblasts were treated with the compounds and concentrations that showed significant activities in breast
tumor cells at 72 h and the results compared with those from MCF-7 and MDA-MB-231 cells. Columns, mean of viable cells; bars, SEM; **P < 0.01 and
***P < 0.001 compared with treated fibroblasts. C, MCF-7 and MDA-MB-231 cells were treated with 4 m, 4bt (dimethylenastron), 4p, 4bc and 4x at the
maximum non-cytotoxic concentration to normal cells for 24 h, 48 h and 72 h and cell viability evaluated in function of time by the MTT assay.
Columns, mean of viable cells; bars, SEM. A, B, C, Data represent the mean ± SEM of three independent experiments in triplicates.
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highly significant. This is exemplified by the 4bc deriva-
tive, which interacts directly with Leu214 and Arg119,
and also has two water-mediated interactions with
Glu116, strongly tying the ligand-binding site (Figure 3).
It is important to note that 4bc derivative interacts withArg119, in a similar way to monastrol, but instead of
interacting with Glu118, it bonds to Glu116, which
ensures stability of the α-helix. The interaction with
Leu214 is also noticeable as 4bc is the only derivative
that binds to residues on both sides of the ligand-
binding site.
Table 2 IC50 and maximum non-cytotoxic concentration
to normal cells established for the five pre-selected
compounds (4 m, 4bt (dimethylenastron), 4p, 4bc and 4x)
and monastrol




4 m 197.3 77.08 1.0
4bt 126.9 17.91 0.8
4p 87.5 68.38 0.4
4bc 234.9 249.5 1.0
4x 276.5 237.4 0.8
Monastrol 110.4 113.9 1.0
These concentrations were determined based on cells treatment for 72 h.
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interaction with Arg119. This interaction occurs both
directly and by water-mediated means, which ensures a
strong linkage between the compound and the residue.
Arg119 also interacts with monastrol and 4bc, highlight-
ing its importance during formation of the Eg5 protein
ligand-binding site (Figure 3).
Derivatives 4 m and 4x interact with the Leu214 resi-
due, but only 4 m interacts with Arg221. All of these dir-
ect interactions involve residues located at this α-helix,
without interacting with residues located at the other
side of the site.
Conversely, 4p does not directly interact with any resi-
due, showing only one water-mediated link to Gly117,
which shows that the related α-helix is of fundamental
importance in the Eg5 catalytic site formation.
Principal component and RMSD analysis
Principal component analysis is a useful tool when the
interest is searching for different motion modes during
simulations [37]. This analysis was performed to confirmFigure 2 DHPM derivatives cause severe morphological alterations on brea
maximum non-cytotoxic concentration to normal cells for 72 h and morph
with elongated morphology, adherent to the surface and normal size are s
points, rounded morphology and detached from the surface where they hthe influence of the first component during the simula-
tion and to clarify the compounds interference on pro-
tein stability.
A comparison of the trajectories (Figure 4A) shows
that 4bc leads the protein to a minor movement during
the simulation. The 4bc derivative restricts protein move-
ment in such a way that the first principal component gets
close to zero in about 20 ns and remains (Figure 4A). De-
rivatives 4 m and 4x act in a similar way, but it is possible
to see that 4 m leads the protein movements to a stabilized
plateau after 40 ns, while 4x remains in an increasing
behavior. Dimethylenastron (4bt), 4p and monastrol are in
the smallest ranges of all projections, but have a final pro-
jection value further from zero than 4bc.
RMSD was also assessed to verify how different the
structure becomes from the initial structural conform-
ation during the simulation. It was noticeable that the
compounds exerted influences of different magnitudes
(Figure 4B): 4bc allowed an important initial shift in the
protein conformation of approximately 0.5 to 20 ns, and
then the structure stabilized; 4 m exerted a significant
influence on the structure until approximately 10 ns,
leading the protein to a shift of almost 0.4 nm; 4x, 4bt
(dimethylenastron) and monastrol displayed a similar in-
fluence on protein changes, leading the RMSD to a plat-
eau of approximately 0.35 nm; and 4p showed the least
important influence, leading the structure to a plateau of
0.3 nm (Figure 4B).
Kinesin Eg5 activity is inhibited in vitro by DHPM derivatives
Inhibition of kinesin Eg5 motor action by DHPMs was
assessed in vitro. Compounds 4bc and 4 m inhibited Eg5
activity in a more pronounced way and were also more
effective than monastrol. 4 m and 4bc reduced the
maximum reaction rate (Vmax) from 18.67 to 16.52 and
15.30, respectively (data not shown). Compounds 4btst cancer cells. MCF-7 and MDA-MB-231 cells were treated with the
ological alterations analyzed under an inverted light microscope. Cells
hown by arrows. Cells with size reduction, absence of focal adhesion
ad been seeded are shown by arrowheads.
Figure 3 3D structure-based models of the Eg5 complexes after the MD assays. Molecular dynamics simulations (MD) of the Eg5 protein and Eg5
protein complexes with each of the five tested compounds were conducted to assess the DHMPs influence on Eg5 movements. The panels show
ribbon representations of the Eg5 and Licorice representations of the tested compounds and monastrol. The yellow dotted lines show the polar
contacts responsible for the maintenance of molecule linkage with the protein binding-site. The binding-region is perfectly conserved, but not
the binding-residues, which lead us to realize the influence of the compound topology. Major differences may be seen in the interactions
between 4 m, 4x and 4p and the Eg5 binding-site, which show completely different binding-residues. However, 4bt and 4bc retain the linkage
with the Arg119 of the Eg5 when comparing to the monastrol, showing its importance in the inhibition processes. Indirect links mediated by
water molecules (cyan), occur in residues (green) annotated in orange; direct links occur with residues annotated in black.
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similar way to monastrol however, this inhibitory activity
was not statistically significant (Figure 4C).
DHPMs treatment induces monoastral spindle formation
and can lead human breast cancer cells to a mitotic
catastrophe phenotype
In order to verify the DHPMs interference with micro-
tubule organization and mitotic spindle formation,
immunofluorescence was performed using anti-α-tubulin
antibody. Four of the five tested compounds (4 m,
dimethylenastron (4bt), 4bc and 4x) caused monoas-
tral spindle formation in MCF-7 cells during mitosis
(Figure 5A), similar to monastrol, as previously reported
[38]. These data corroborate our results obtained from the
in vitro Kinesin inhibition assay, indicating that these
compounds are indeed effective inhibitors of this protein
activity. The percentage of cells with monoastral spindles
that accumulate in asynchronous populations of MCF-7
cells treated for 24 h and 48 h is shown in Additional
file 3: Table S1.
Treatment of MCF-7 cells with 4p (0.4 mM) produced
a quite distinct pattern of microtubules organization, notobserved for the other compounds/derivatives. Treated
cells showed disruption of the microtubules, which were
disordered and appeared to be concentrated in per-
ipheral cell areas, adjacent to the plasmatic membrane
(Figure 5A). Another observed change was the nuclear
fragmentation phenotype with multiple micronuclei for-
mation (Figure 5B), a common characteristic of a mitotic
catastrophe.
In order to confirm that 4p treated cells undergo mi-
totic catastrophe, a supplementary transmission electron
microscopy (TEM) analysis of these samples was per-
formed. Treated cells showed nuclear fragmentation evi-
denced both by DAPI staining and TEM (Figure 5B).
Plasma membrane integrity and a perinuclear vacuoliza-
tion (Figure 5B) were also observed in a small number
of cells from this sample. These observations strongly
indicate that 4p treatment leads cells to a mitotic catas-
trophe phenotype [39].
DHPMs-induced cell death occurs mainly by apoptosis
We subsequently determined the type of cell death in-
duced by DHPM derivatives in breast cancer cells. The
majority of cells from both cell lines died by apoptosis
Figure 4 4bc leads Eg5 to a very restricted conformation and potently inhibits this protein in vitro. A, Essential dynamics analysis over time was
performed to assess the DHPMs interference on Eg5 protein stability. Values far from zero mean that the structure has greater movement
amplitude in its first principal component. It is possible to note that compound 4bc leads the protein to a more stable conformation after the
MD assays. B, RMSD from the initial structure over time. Compound 4bc allows the greatest initial shift compared to the other molecules, but all
of them lead the protein to a stable conformation after about 15 ns. C, Inhibitory rate of Eg5 by DHPMs in vitro. Kinesin Eg5 (1 μg) was incubated
with the IC50 of 4 m, 4bt (dimethylenastron), 4p, 4bc, 4x and monastrol with readings taken immediately after incubation at room temperature at
30 second intervals for a total reaction time of 30 minutes. Reactions were measured in spectrophotometer set in kinetic mode and an absorbance
wavelength of 360 nm. Dots, mean of nmols of phosphate versus reaction time. *P < 0.05.
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However, 4bc and 4bt (dimethylenastron) derivatives
showed remarkable cell death induction, translated on
antitumor activity. The 4bc derivative led to cell death
by apoptosis: 92% and 97% of MCF-7 and MDA-MB-
231 cell populations, respectively. Dimethylenastron
(4bt) induced apoptosis in 39% and 83% of cell popula-
tions in MCF-7 and MDA-MB-231, respectively; thus
showing similar activity to that recorded for monastrol
(Figure 6A). The other compounds (4 m, 4p and 4x) also
caused cell death by apoptosis, although a less pro-
nounced manner.
These results indicate that treatment with DHPMs can
foster a significant decrease in cell viability. Interestingly,
the MDA-MB-231 cells are more susceptible to cell
death induction by DHPM derivatives than MCF-7 cells.
Minor doses and shorter treatment periods were suffi-
cient to induce a high number of MDA-MB-231 cells todeath (Figure 1A and C). Therefore, a large number of
dead cells were found with a late apoptosis profile after
72 h of treatment and not in early apoptosis as for
MCF-7 cells (Figure 6A).
DHPM derivatives potently repress breast tumor cell
proliferation
Proliferation is a crucial process in the maintenance and
progression of cancer cells. Therefore, we monitored the
effects of DHPM derivatives on proliferation of breast
cancer cells, MCF-7 and MDA-MB-231, by using a CFSE
assay followed by flow cytometry analysis after 72 hours of
treatment.
Significant inhibition of the proliferation pattern was
shown by the samples treated with 4 m, 4bt (dimethylenas-
tron), and 4p both in MCF-7 and in MDA-MB-231 cells, as
was also observed for monastrol treatment. Approximately
50% of cell proliferation was inhibited after treatment with
Figure 5 DHPMs produce monoastral spindles and 4p can lead cancer cells to a mitotic catastrophe phenotype. A, MCF-7 cells exposed to 4 m
(1.0 mM), 4bt (dimethylenastron, 0.8 mM), 4p (0.4 mM), 4bc (1.0 mM), 4x (0.8 mM), monastrol (0.1 mM – positive control) or to culture medium
only (negative control) for 24 h were immunostained with α-tubulin (green) and DNA stained with DAPI (blue). Cells were analyzed under a laser
scanning confocal microscope. B, MCF-7 cells control or treated with 4p (0.4 mM) for 24 h had their nucleus stained with DAPI (left panels) or
were processed and analyzed by Transmission Electron Microscopy after exposure to 4p (0.4 mM) for 48 h (right panels). Treated cells (lower
panels) showed nuclear fragmentation with multiple micronuclei formation (MN), perinuclear vacuolization (V) and maintenance of cell
membrane integrity (black arrows) compared to untreated cells (upper panels) showed nuclei with normal morphology and integrity (N) and
(white arrowhead).
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antiproliferative activity, but at a lower level.
Treatment with some DHPMs may result in cell cycle
arrest in G2/M phase
In order to evaluate if DHPMs could impair normal cell
cycle progression, the influence of the compounds on
MCF-7 and MDA-MB-231 cells treated for 24, 48 and
72 h were analyzed. Our results demonstrated that after
48 h treatment, compounds 4 m, 4p and 4x caused a cell
cycle arrest at G2/M in MCF-7 cells. The derivatives
with high cytotoxic activity, 4bt (dimethylenastron) and
4bc, led to a decrease of cells in G2/M and an increaseof cells in S phase (Figure 6C, left panel). Regarding
MDA-MB-231 cells, only the 4 m derivative was able to
cause cell arrest in G2/M. When considered in conjunc-
tion, these results indicate that this arrest in G2/M could
not be observed in the treatments with more cytotoxic
compounds because of the rapid cell elimination. No
other significant change was observed in any stage of the
cell cycle compared to the untreated control (Figure 6C,
right panel). Results after 24 h and 72 h of treatment
were less significant. Only the 4 m caused cell cycle ar-
rest in G2/M in MCF-7 cells after 24 and 72 h of treat-
ment and no alterations occurred in MDA-MB231
treated cells in these times (Additional file 4: Figure S2).
Figure 6 DHPMs potently repress breast tumor cell proliferation, induce apoptosis and modulate the CSC phenotype. MCF-7 and MDA-MB-231 cells control
or cells treated with 4 m (1.0 mM), 4bt (dimethylenastron 0.8 mM), 4p (0.4 mM), 4bc (1.0 mM), 4x (0.8 mM) and monastrol (1 mM) were analyzed by flow
cytometry to assess: the type of cell death caused by treatment for 72 h by staining cells with Annexin-V and PI (A); the ability to inhibit cell proliferation
after 72 h of DHPM exposure, using CellTrace™ CFSE (B); the cell cycle profile after 48 h of treatment by staining the DNA content with PI (C); and the CSC
population after 24 h of treatment, evaluating the CD44 and CD24 expression (D). Columns, mean of cells; bars, SEM, *P < 0.05; **P < 0.01; ***P < 0.001. All
analyzes were performed in three independent experiments.
Guido et al. BMC Cancer  (2015) 15:283 Page 11 of 15DHPMs lead to a decrease in the breast CSC subpopulation
In breast cancer, a subset of markers, including: CD44hi/
CD24lo, aldehyde dehydrogenase, Hoechst dye efflux, and
the retention of the PKH26 lipophilic dye, have been shown
to enrich CSC in various cell lines [40-42]. To investigate
whether the DHPMs could influence the phenotypic profile
on breast cancer cell subpopulations, CD44 and CD24 sur-
face markers were evaluated in MCF-7 and MDA-MB-231
cells treated with each of the five derivatives.
The MCF-7 cells have a very small population of cancer
stem cells with an average of 0.38% for CD44+/CD24−
cells. The treatment with DHPM has no impact on the
expression of these markers and therefore does not
change the amount of CSC in the MCF-7 cell population
(Figure 6D and Additional file 5: Table S2). However, the
results were extremely interesting regarding the influence
of DHPM in modulating the expression of these molecules
in MDA-MB-231 cells. Derivatives 4bt (dimethylenastron)
and 4bc significantly decreased the CD44+/CD24− sub-
population from 98.45% (untreated control) to appro-
ximately 47.83% and 14.84%, respectively (Figure 6D and
Additional file 6: Table S3). We also observed a significant
increase in the CD44+/CD24+ phenotype in samples
treated with these derivatives. These results indicate
that 4bt (dimethylenastron) and 4bc compounds might beinducing a transition of MDA-MB-231 cells to a more
epithelial profile.DHPM derivatives inhibit angiogenesis both in vitro and
in vivo
The effects of DHPM treatment on tube formation were
evaluated in vitro using HUVEC cells, and in vivo using
a model on chorioallantoic membrane (CAM) of fertil-
ized chicken eggs. The in vitro assay demonstrated that
HUVEC cells were capable of building tubes by connect-
ing to neighboring cells forming a rich meshwork of
branching capillary-like tubules (Figure 7A). However,
following DHPM treatment at different concentrations
(30 μM, IC50 and 300 μM), the intercellular connection
was abrogated and HUVEC cells failed to form tubes.
It was observed at the higher concentration that the
capillary-like tubes were interrupted and most cells pre-
sented spherical morphology, either in isolation or aggre-
gated in small clumps (Figure 7A). In addition, all the
compounds resulted in a significant decrease in HUVEC
tube formation mainly at the higher concentration
(300 μM) as quantified by patter recognition (Figure 7A
right panel). Derivatives 4p and 4bt (dimethylenastron)
were associated with the more pronounced anti-angiogenic
Figure 7 DHPM derivatives inhibit angiogenesis both in vitro and in vivo. A, Tube formation analysis by HUVEC cells seeded onto the surface of the
polymerized ECMatrix™ in 96-well plates after 11 h of treatment with 4 m, 4bt (dimethylenastron), 4p, 4bc, 4x and monastrol. Representative images of
cells treated with 300 μM of each compound documented using an inverted light microscope at 20x magnification (left panel). Tube-like structures
formed by HUVEC cells control (asterisks) or cells exposed to 30 μM, IC50 or 300 μM of 4 m, 4bt (dimethylenastron), 4p, 4bc, 4x and monastrol for 11 h,
which have lost their ability to cluster in tube-like structures (arrows), were quantified by pattern recognition (right panel). Columns, means of scored
tube formation; bars, SEM; **P < 0.01; ***P < 0.001 compared with untreated control. Seven frames per group of three independent experiments
(n = 1) were quantified. B, Chorioallantoic membrane (CAM) tumor assay. MCF-7 and MDA-MB-231 cells control or treated with 500 ng of 4 m, 4bt
(dimethylenastron), 4p, 4bc, 4x, monastrol or genistein (antiangiogenic control) were implanted into CAM and on the 17th day of development the
quantification of total nets was performed by Wimasis Image Analysis (left panel). Columns, mean of total nets (n = 3–5); bars, SEM. A representative
image of the most effective treatment for each cell compared with the respective controls can be observed (right panels).
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properties substantially interfered with the ability of
HUVEC to form capillary-like structures in vitro.
To assess whether DHPM derivatives could also
inhibit vessel formation by breast tumor cells, an
in vivo model based on CAM of fertilized chicken
eggs was performed. These results indicated that allderivatives were capable of subtly inhibiting new
blood vessel formation at very low doses (500 ng)
(Figure 7B). Although the anti-angiogenic properties
presented by DHPM on the CAM assay were not
statistically significant, our data suggests a marked
reduction in vessel convergence toward tumor cell
implantation and vessel thickness (Figure 7B - right
Guido et al. BMC Cancer  (2015) 15:283 Page 13 of 15panel). It is probable that the reduction in the total num-
ber of networks formed by vessels would be much more
exacerbated at higher concentrations.
Discussion
In this study, we conducted an in vitro examination of the
different aspects of cytotoxicity induced by 3,4-dihydropyri-
midin-2(1H)-one (or thione) derivatives in MCF-7 and
MDA-MB-231 cells. Several results suggest that DHPMs
can inhibit kinesin Eg5 in a specific manner, leading to a
critical error in mitotic spindle assembly, which in turn
induces cell death by apoptosis. Apoptosis induction of
cancer cells is the most pursued goal in drug development,
as recently reviewed [43], due to its natural clearance effect,
no association with inflammatory mechanisms, and its
related role in tissue regeneration [44].
Cell proliferation is a crucial process relating to cancer
initiation, maintenance and progression [45]. In our
studies, cell treatments with low concentrations of 4 m,
4bt (dimethylenastron), and 4p derivatives act primarily
by preventing cell proliferation in both cell lines. These
data suggest a very interesting DHPM cytostatic effect
which is a useful property in targeting cancer cells that
are resistant to apoptosis induction and have a poor re-
sponse to proapoptotic agents.
Another very interesting finding was that at much
lower concentrations, compound 4p showed high cyto-
toxic activity on breast tumor cells, however this effect
was also well pronounced on normal cells which is prob-
ably due to the fact that this compound binds to another
target rather than the Eg5 motor protein. Despite its lack
of direct interaction with kinesin Eg5, as demonstrated
by MD analysis (Figure 3) and visualized by α-tubulin
immunostaining (Figure 5A), 4p was able to induce cell
death by mitotic catastrophe (Figure 5B).
According to Vitale and coworkers (2011), failing mi-
toses are often associated with chromosomal breakages
and deficient karyokinesis, which lead to gross nuclear
alterations (micronucleation and multinucleation) that
constitute the most prominent morphological traits of
mitotic catastrophe [46,47]. In addition, other typical
features of this event are mitosis blockage, mitotic spin-
dle disorganization and chromosome segregation failure
[41]. Due to the activation of several death pathways fol-
lowing mitotic catastrophe, the induction of this event is
considered a valid mechanism to subvert drug resistance
[48]. It was also shown that molecules such as monastrol,
dimethylenastron (4bt), K858 and ARRY-520 are able to
trigger mitotic catastrophe and cell death by inhibiting
kinesin [11,49,50].
Our results indicated 4bc as a potent and specific anti-
tumor agent. This molecule showed dose-dependent
lethal action against tumor cells, but not for normal cells,
and together with 4bt (dimethylenastron) is consideredthe most promising of the compounds tested. These
results corroborate molecular dynamics data, in which
reveals these compounds form more stable bonds with
Eg5 protein residues, and these connections are made in
the common residues that monastrol binds to [51]. The
binding-site sealing, promoted by the linkage of 4bc,
prominently inhibit protein mobility, causing a significant
reduction of its major mobility-dependent functions. The
MD results show that this mechanism of action can be the
main cause of Eg5 inhibition by 4bc. Since the other com-
pounds did not show a relevant stiffening promotion, as
observed for 4bc, it is possible to assume that there is a
strong relationship between protein movements and its
activity. Furthermore, it is possible to understand the im-
portance of Arg119 in catalytic binding-site formation,
since the majority of inhibitory molecules interact with
this residue. Reviewing the essential dynamics and RMSD
results; it is easy to see that 4bc leads Eg5 structure
to an interesting shift, and ultimately to an important
stabilization, different from the other compounds. This
stabilization in a different structural conformation may be
the key to the competitive inhibition of Eg5 activity.
In addition to these properties, 4bc and 4bt (dimethy-
lenastron) also affect a very important property of tumor
establishment and maintenance - the presence of cancer
stem cells. CSC are defined by their tumor-initiating prop-
erties which appear to be responsible for driving tumor
growth, recurrence, and metastasis [40,52]. We detected a
considerable decrease in CSC population (CD44+/CD24−)
in MDA-MB-231 cells treated with 4bc and 4bt (dimethy-
lenastron) and an increase in the CD44+/CD24+ popula-
tion. This was a surprising result in that it was previously
verified that CSC isolated from breast cancer cell lines are
resistant to radiation and chemotherapy [53,54]. Further-
more, these treatments can select for the outgrowth of
therapy-resistant cancer cell subpopulations that are more
tumorigenic, invasive, and stem like [55,56]. Hence, cancer
therapies may be rendered ineffective because the bulk of
cancer cells within a tumor may be eliminated while leav-
ing slow cycling cells behind, such as CSC which are also
resistant to apoptosis and proceed to regenerate the tumor
[57-59]. This alteration in cells that become more epithe-
lial (CD44+/CD24+) [60] allowed them to acquire suscep-
tibility to cytotoxic effects produced by DHPMs or other
anticancer agents. Further studies are necessary in order
to characterize the molecular aspects related with CSC
under DHPMs derivatives treatment.
Conclusions
Our results provide evidence of potent Eg5 inhibitors,
the DHPMs derivatives, which prevent normal mitotic
spindle formation during cell division inducing breast
tumor cells to apoptosis, besides to show that several cel-
lular processes are impaired by DHPMs activity differently
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tumoral cells. Thus, the major overall findings obtained
from the analyses are:
i) DHPM derivatives are potent Eg5 inhibitors
and have potent activity against MCF-7 and
MDA-MB-231 cells with low cytotoxicity to normal
cells affording a great advantage over current
drugs widely used in cancer treatment;
ii) Two compounds (4bt and 4bc) are more efficient
than monastrol, a widely recognized inhibitor of
Eg5 activity;
iii)The DHPMs are able to interfere, in vitro, with the
development of essential properties for tumor
establishment and progression such as cell
proliferation, angiogenesis, and CSC phenotype;
iv) The cytotoxic effect of DHMPs is accompanied
by the induction of apoptosis in MCF-7 and
MDA-MB-231 cells
v) DHPM architecture is a promising
chemotherapeutic candidate because of its selective
bioactivity in tumor cells, which should be further
evaluated by in vivo assays.
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